Welcome to the Third 2020 Issue of The CLL Society Tribune focused on MRD
This is the first of several single-issue Tribunes where we can dive deeper into evolving or important topics and recent research findings. Next quarter we will focus on CAR-T therapy, but in this season’s issue we focus our spotlight on MRD, also known as minimal or measurable residual disease. Over the next few years, the role of MRD testing in determining when certain CLL treatments might be safely stopped is expected to become more important. But that is true only in some circumstances and only with some therapies. Patients can prepare by becoming well-informed so as to know when to push for appropriate testing. Please complete our MRD and limited duration survey, and then please read all that we have prepared from patients and experts on this emerging topic, because Smart Patients Get Smart Care™.
Read about Stephen’s experience of having achieved undetectable minimal residual disease status (U-MRD) … Read more
CLL Society is asking for patient and caregiver participation in a survey which will help us learn about knowledge, attitudes, and preferences about MRD (measurable residual disease or minimal residual disease) and limited duration (also known as fixed duration) therapies. Our goal is to learn more about what our patients know and think so we can best serve you in the future. Please take a few minutes to complete this important survey. … Go to survey!
Learn more about MRD and disease monitoring by visiting our webpage here.
NEW IN 2020!
Submit your stories and questions regarding CAR-T Therapy for our Q4 Special Edition Tribune to email@example.com!
CLL Tribune is looking for your contribution including articles, storytelling, poems, drawings, or other creative mediums. Please share!
Email firstname.lastname@example.org with your interest!
Dr. Koffman breaks down the key takeaways from a recent medical article that describes the MRD landscape. … Read more
Read Dr. Leclair’s two articles that will give you the opportunity to gain helpful insights, not only into understanding your own CLL test results, but also to acquire a good grasp of the current data about COVID-19 results and any other testing data … Read more
At ASH 2019 in Orlando, Dr. Brian Koffman interviewed Dr. Constantine Tam about the most recent results of the Captivate Trial – Ibrutinib + Venetoclax in First-Line Treatment. … Watch The Interview
Questions submitted by readers and answered by our CLL Society experts.
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society…Read more
Thomas E Henry III, MBA, RPh, CPh from Burlington Consulting Associates answers readers’ pharmacy questions submitted to the CLL Society…Read more
Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society…Read more
Dr. Ratner at the Minneapolis VA Medical Center answers readers’ hospice/palliative care questions submitted to the CLL Society…Read more
The CLL Society Tribune is made possible in part by grant support from AbbVie, Adaptive Biotechnologies, Astra Zeneca, and Genentech.
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.